Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

NCT01049425 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT01049425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01049425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Phase 3
Overall status
Completed
Start date
February 5, 2009
Completion date
May 15, 2018
Enrollment
3,198 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 non-overexpressing, primary breast cancer